Table 2.
Binding site and mechanism of action of SARS-CoV-2 specific mAbs discussed in this review.
| Groups of Specific mAbs | Name | Binding Site and Mechanism of Action |
|---|---|---|
| MAbs isolated from SARS-CoV-2 patients | B5 | SARS-CoV-2 RBD; partial competition with ACE2 |
| B38 | SARS-CoV-2 RBD; complete competition with ACE2 | |
| H2 | SARS-CoV-2 RBD; no competition with ACE2 | |
| H4 | SARS-CoV-2 RBD; complete competition with ACE2 | |
| EY6A | SARS-CoV-2 RBD and SARS-CoV RBD with lower affinity; site spatially separate from that of ACE2 | |
| MAbs that cross-neutralize SARS-CoV and SARS-CoV-2 | 47D11 | SARS-CoV-2 and SARS-CoV RBD; conserved epitope in the RBD |
| CR3022 | SARS-CoV RBD and SARS-CoV-2 RBD with lower affinity; conserved epitope in the RBD. Do not neutralize SARS-CoV-2 | |
| MAbs that have received Emergency Use Authorization (EUA) | Bamlanivimab (LY-CoV555) | SARS-CoV-2 RBD; EUA revoked |
| Casirivimab (REGN10933) and imdevimab (REGN10987) in a combined therapy | Non-overlapping epitopes of the SARS-CoV-2 RBD | |
| Bamlanivimab (LY-CoV555) and etesevimab (LY-CoV016) in a combined therapy | Different, but overlapping, epitopes of the SARS-CoV-2 RBD |